Eli Lilly and Company (LLY): I Would 'Love' If Trump Praised The Company, Says Jim Cramer
Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed pharmaceutical stocks on Cramer's morning show. Over the course of this year, the CNBC TV host has maintained that the firm enjoys a lead in the weight loss drug market and aims to further expand its dominance by developing a robust manufacturing base. Cramer also believes that Eli Lilly and Company (NYSE:LLY) will benefit from introducing a weight loss pill along with a strong pipeline of drugs that targets diseases such as hypertension. His recent comments focused on an analyst note:
'[On a Mizuho note saying POTUS would praise LLY and JNJ] I would love that, that won't happen. You know why it won't happen? See there's someone in the health and human services department that's not crazy about, about big pharma and the way we think about it. So there's not going to be a party thrown for you at Lilly. You know that GLP-1 is not a favorite of RFK Jr. Not a favorite. So no, no party for them.'
Earlier, Cramer discussed Eli Lilly and Company (NYSE:LLY)'s CEO and investor expectations:
'David Ricks, if you spend time with him, has a view, of what should be done, that ends with the pill that you take every day, no shot . . but everyone's thinking that he doesn't have anything in the hopper. He's got heart coming up, he's going to have Alzheimer's coming up, oh buy.
An array of pharmaceutical pills with the company's logo on the bottle.
'It's going be a trillion-dollar market cap, Ken Langone told me that. He's one of the largest investors in Lilly. He knows.
While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
34 minutes ago
- Business Insider
Jim Cramer Says Rocket Lab (RKLB) Is ‘One Of The Hottest Stocks In The Universe'
Rocket Lab (RKLB) stock surged higher on Monday after the launch services and space systems solutions company received praise from Jim Cramer. He called it 'one of the hottest stocks in the universe' during CNBC's Mad Money Lightning Round. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Rocket Lab stock also received updated coverage from Citi analysts. The firm's analysts maintained a Buy rating for RKLB stock and increased their price target to $50 from $33, suggesting a possible 18.7% upside for the shares. The increased price target for RKLB stock came alongside a preview of the aerospace and defense sector's Q2 earnings. According to the Citi analysts, this market has experienced strong momentum recently and they expect this trend to continue. Rocket Lab Stock Movement Today Rocket Lab stock was up 8.43% on Monday morning alongside the praise from Cramer and the increased Citi price target. This extended the company's recent rally, which included a year-to-date increase of 66.16%. Investors who have held RKLB stock over the past 12 months have seen their shares increase in value by 582.34%. Additional catalysts are on the horizon for Rocket Lab stock. The company will likely release its Q2 2025 earnings report on Aug. 7, 2025. Wall Street expects the space company to report adjusted earnings per share of -9 cents alongside $134.4 million in revenue. Its chances of beating these estimates are mixed based on data from its previous eight quarters. Is Rocket Lab Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Rocket Lab is Moderate Buy, based on eight Buy and three Hold ratings over the past three months. With that comes an average RKLB stock price target of $32, representing a potential 23.72% downside for the shares.
Yahoo
an hour ago
- Yahoo
UBS Upgrades Altria Group (MO) as E-Cigarette Crackdown Supports Earnings Stability
Altria Group, Inc. (NYSE:MO) ranks among the . On July 2, UBS raised its price target for Altria Group, Inc. (NYSE:MO) from $47 to $59 and upgraded it from Sell to Neutral. The firm stated that stronger regulation against illegal e-cigarette imports, especially from China, might reduce pressure on cigarette volumes and maintain earnings growth. The increase in enforcement, according to UBS, might improve industry trends by approximately 100 basis points, reducing the annual fall in cigarette volumes to -8% from a previous prediction of 9% or worse. Due to improved volume performance, cost reductions of more than $600 million, and targeted price investment in its affordable Basic brand, UBS now projects that Altria's earnings would remain stable through 2026. UBS anticipates that Altria Group, Inc. (NYSE:MO) will post a 10.5% decline in cigarette shipments and group earnings per share of $1.41, somewhat higher than the $1.38 consensus, ahead of the company's second-quarter results. Altria Group, Inc. (NYSE:MO) is a prominent American company that produces and markets tobacco, cigarettes, and associated products on a global scale. The firm has also ventured into next-generation nicotine products, such as oral nicotine pouches and electronic vaping devices. While we acknowledge the potential of MO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
McCormick (MKC) Shows Strength Despite Tariff Pressures, Says Bernstein
McCormick & Company, Incorporated (NYSE:MKC) ranks among the . The Bernstein SocGen Group kept its Market Perform rating on McCormick & Company, Incorporated (NYSE:MKC) while increasing its price target from $101 to $102 on June 27. The change comes after Bernstein characterized McCormick's second-quarter 2025 performance as 'solid.' Since McCormick & Company, Incorporated (NYSE:MKC) sources around 17,000 ingredients from about 90 countries, its supply chain is more globally exposed than that of many other food manufacturers. As such, the company is subject to a 30% tariff on imports from China and a 10% tariff on imports from the most other nations. According to Bernstein, these tariffs will raise McCormick's cost of goods sold by an incremental 2% annually. McCormick's ability to stick to its guidance while absorbing these tariff headwinds, according to the firm, shows 'the strength of the underlying business.' American food company McCormick & Company, Incorporated (NYSE:MKC) produces, distributes, and supplies the food industry as a whole with seasoning mixes, condiments, spices, and other products. While we acknowledge the potential of MKC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
